Invex Therapeutics (ASX:IXC) Liabilities-to-Assets : 0.04 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Invex Therapeutics Liabilities-to-Assets?

Invex Therapeutics ASX:IXC -4.76% Liabilities-to-Assets is 0.04 as of Dec. 2025. The stock has 1 warning sign investors should review.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Invex Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 was A$0.18 Mil. Invex Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was A$4.72 Mil. Therefore, Invex Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2025 was 0.04.

Invex Therapeutics  (ASX:IXC) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Invex Therapeutics Liabilities-to-Assets Related Terms

Invex Therapeutics Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Liabilities-to-Assets Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Liabilities-to-Assets
Get a 7-Day Free Trial 0.02 0.03 0.07 0.07 0.04

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.07 0.08 0.04 0.04

ASX:IXC vs VRTX, REGN, ALNY: Liabilities-to-Assets Comparison

For the Biotechnology subindustry, Invex Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics Liabilities-to-Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Liabilities-to-Assets falls into.


Invex Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Invex Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2025 is calculated as:

Liabilities-to-Assets (A: Jun. 2025 )=Total Liabilities/Total Assets
=0.221/5.468
=0.04

Invex Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2025 is calculated as

Liabilities-to-Assets (Q: Dec. 2025 )=Total Liabilities/Total Assets
=0.176/4.723
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 0.04 mean?
Invex Therapeutics (ASX:IXC) has a Liabilities-to-Assets of 0.04 as of Dec. 2025. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Liabilities-to-Assets too high?
Invex Therapeutics' current Liabilities-to-Assets is 0.04.
How does Invex Therapeutics' Liabilities-to-Assets compare to VRTX and REGN?
Invex Therapeutics' Liabilities-to-Assets of 0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Liabilities-to-Assets is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Liabilities-to-Assets of 0.04. The current Liabilities-to-Assets is 0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Liabilities-to-Assets is 0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.